APO Research
Talk to an analyst

APO RESEARCH · REPORT

Women's Health Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Women's Health Drugs Market Outlook and Growth Opportunities 2026

23 December 2025190 pages

Choose your research edition.

Industry ResearchWomen's Health Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Women's Health Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Women's Health Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Women's Health Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Women's Health Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Women's Health Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Women's Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Women's Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Women's Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Women's Health Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Women's Health Drugs market include Merck & Co., Pfizer, GlaxoSmithKline, Bayer AG, AbbVie Inc, Therapeutics MD and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Women's Health Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Women's Health Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Women's Health Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Women's Health Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Women's Health Drugs Segment by Company

Merck & Co.

Pfizer

GlaxoSmithKline

Bayer AG

AbbVie Inc

Therapeutics MD

Allergan Plc

Women's Health Drugs Segment by Type

Contraceptives Drug

Infertility Drug

Polycystic Ovary Syndrome Drug

Menopause Drug

Postmenopausal Osteoporosis Drug

Endometriosis Drug

Others

Women's Health Drugs Segment by Application

Elderly Women

Young Women

Little Girls

Women's Health Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Women's Health Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Women's Health Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Women's Health Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Women's Health Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women's Health Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Women's Health Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women's Health Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Women's Health Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Women's Health Drugs industry.

Chapter 3: Detailed analysis of Women's Health Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Women's Health Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Women's Health Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Women's Health Drugs Industry Trends Table 2. Women's Health Drugs Industry Drivers Table 3. Women's Health Drugs Industry Opportunities and Challenges Table 4. Women's Health Drugs Industry Restraints Table 5. Global Women's Health Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Women's Health Drugs Revenue Share by Company (2021-2026) Table 7. Global Women's Health Drugs Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Women's Health Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Women's Health Drugs Average Price (US$/kg) of Company (2021-2026) Table 10. Global Women's Health Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Women's Health Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Women's Health Drugs Company, Product Type & Application Table 13. Global Women's Health Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Women's Health Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Contraceptives Drug Table 18. Significant Companies of Infertility Drug Table 19. Significant Companies of Polycystic Ovary Syndrome Drug Table 20. Significant Companies of Menopause Drug Table 21. Significant Companies of Postmenopausal Osteoporosis Drug Table 22. Significant Companies of Endometriosis Drug Table 23. Significant Companies of Others Table 24. Global Women's Health Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 25. Global Women's Health Drugs Sales Volume by Type (2021-2026) & (k tons) Table 26. Global Women's Health Drugs Sales Volume by Type (2027-2032) & (k tons) Table 27. Global Women's Health Drugs Sales Volume Share by Type (2021-2026) Table 28. Global Women's Health Drugs Sales Volume Share by Type (2027-2032) Table 29. Global Women's Health Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Women's Health Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Women's Health Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Women's Health Drugs Sales Value Share by Type (2021-2026) Table 33. Global Women's Health Drugs Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Elderly Women Table 35. Significant Companies of Young Women Table 36. Significant Companies of Little Girls Table 37. Global Women's Health Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 38. Global Women's Health Drugs Sales Volume by Application (2021-2026) & (k tons) Table 39. Global Women's Health Drugs Sales Volume by Application (2027-2032) & (k tons) Table 40. Global Women's Health Drugs Sales Volume Share by Application (2021-2026) Table 41. Global Women's Health Drugs Sales Volume Share by Application (2027-2032) Table 42. Global Women's Health Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Women's Health Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Women's Health Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Women's Health Drugs Sales Value Share by Application (2021-2026) Table 46. Global Women's Health Drugs Sales Value Share by Application (2027-2032) Table 47. Global Women's Health Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 48. Global Women's Health Drugs Sales by Region (2021-2026) & (k tons) Table 49. Global Women's Health Drugs Sales Market Share by Region (2021-2026) Table 50. Global Women's Health Drugs Sales by Region (2027-2032) & (k tons) Table 51. Global Women's Health Drugs Sales Market Share by Region (2027-2032) Table 52. Global Women's Health Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Women's Health Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Women's Health Drugs Sales Value Share by Region (2021-2026) Table 55. Global Women's Health Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Women's Health Drugs Sales Value Share by Region (2027-2032) Table 57. Global Women's Health Drugs Market Average Price (US$/kg) by Region (2021-2026) Table 58. Global Women's Health Drugs Market Average Price (US$/kg) by Region (2027-2032) Table 59. Global Women's Health Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 60. Global Women's Health Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Women's Health Drugs Sales by Country (2021-2026) & (k tons) Table 62. Global Women's Health Drugs Sales Market Share by Country (2021-2026) Table 63. Global Women's Health Drugs Sales by Country (2027-2032) & (k tons) Table 64. Global Women's Health Drugs Sales Market Share by Country (2027-2032) Table 65. Global Women's Health Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Women's Health Drugs Sales Value Market Share by Country (2021-2026) Table 67. Global Women's Health Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Women's Health Drugs Sales Value Market Share by Country (2027-2032) Table 69. Merck & Co. Company Information Table 70. Merck & Co. Business Overview Table 71. Merck & Co. Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 72. Merck & Co. Women's Health Drugs Product Portfolio Table 73. Merck & Co. Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 77. Pfizer Women's Health Drugs Product Portfolio Table 78. Pfizer Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Women's Health Drugs Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Bayer AG Company Information Table 85. Bayer AG Business Overview Table 86. Bayer AG Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 87. Bayer AG Women's Health Drugs Product Portfolio Table 88. Bayer AG Recent Development Table 89. AbbVie Inc Company Information Table 90. AbbVie Inc Business Overview Table 91. AbbVie Inc Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 92. AbbVie Inc Women's Health Drugs Product Portfolio Table 93. AbbVie Inc Recent Development Table 94. Therapeutics MD Company Information Table 95. Therapeutics MD Business Overview Table 96. Therapeutics MD Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 97. Therapeutics MD Women's Health Drugs Product Portfolio Table 98. Therapeutics MD Recent Development Table 99. Allergan Plc Company Information Table 100. Allergan Plc Business Overview Table 101. Allergan Plc Women's Health Drugs Sales (k tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 102. Allergan Plc Women's Health Drugs Product Portfolio Table 103. Allergan Plc Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Women's Health Drugs Distributors List Table 107. Women's Health Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Women's Health Drugs Product Image Figure 2. Global Women's Health Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Women's Health Drugs Sales (2021-2032) & (k tons) Figure 5. Global Women's Health Drugs Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Women's Health Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Contraceptives Drug Image Figure 10. Infertility Drug Image Figure 11. Polycystic Ovary Syndrome Drug Image Figure 12. Menopause Drug Image Figure 13. Postmenopausal Osteoporosis Drug Image Figure 14. Endometriosis Drug Image Figure 15. Others Image Figure 16. Global Women's Health Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 17. Global Women's Health Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Women's Health Drugs Sales Volume Share by Type (2021-2032) Figure 19. Global Women's Health Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Women's Health Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Women's Health Drugs Sales Value Share by Type (2021-2032) Figure 22. Elderly Women Image Figure 23. Young Women Image Figure 24. Little Girls Image Figure 25. Global Women's Health Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Women's Health Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Women's Health Drugs Sales Volume Share by Application (2021-2032) Figure 28. Global Women's Health Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Women's Health Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Women's Health Drugs Sales Value Share by Application (2021-2032) Figure 31. Global Women's Health Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 32. Global Women's Health Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Women's Health Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Women's Health Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. North America Women's Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Women's Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Women's Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. South America Women's Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Women's Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Women's Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Women's Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Women's Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Women's Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Women's Health Drugs Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Women's Health Drugs Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Contraceptives Drug
  • Infertility Drug
  • Polycystic Ovary Syndrome Drug
  • Menopause Drug
  • Postmenopausal Osteoporosis Drug
  • Endometriosis Drug
  • Others
Applications
  • Elderly Women
  • Young Women
  • Little Girls
Companies covered
  • Merck & Co.
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • AbbVie Inc
  • Therapeutics MD
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Women's Health Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Women's Health Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Women's Health Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Women's Health Drugs Market Dynamics
  1. 2.1 Women's Health Drugs Industry Trends
  2. 2.2 Women's Health Drugs Industry Drivers
  3. 2.3 Women's Health Drugs Industry Opportunities and Challenges
  4. 2.4 Women's Health Drugs Industry Restraints
3 Women's Health Drugs Market by Company
  1. 3.1 Global Women's Health Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Women's Health Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Women's Health Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Women's Health Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Women's Health Drugs Company Ranking (2024-2026)
  6. 3.6 Global Women's Health Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Women's Health Drugs Company Product Type and Application
  8. 3.8 Global Women's Health Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Women's Health Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Women's Health Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Women's Health Drugs Market by Type
  1. 4.1 Women's Health Drugs Type Introduction
  2. 4.1.1 Contraceptives Drug
  3. 4.1.2 Infertility Drug
  4. 4.1.3 Polycystic Ovary Syndrome Drug
  5. 4.1.4 Menopause Drug
  6. 4.1.5 Postmenopausal Osteoporosis Drug
  7. 4.1.6 Endometriosis Drug
  8. 4.1.7 Others
  9. 4.2 Global Women's Health Drugs Sales Volume by Type
  10. 4.2.1 Global Women's Health Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Women's Health Drugs Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Women's Health Drugs Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Women's Health Drugs Sales Value by Type
  14. 4.3.1 Global Women's Health Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Women's Health Drugs Sales Value by Type (2021-2032)
  16. 4.3.3 Global Women's Health Drugs Sales Value Share by Type (2021-2032)
5 Women's Health Drugs Market by Application
  1. 5.1 Women's Health Drugs Application Introduction
  2. 5.1.1 Elderly Women
  3. 5.1.2 Young Women
  4. 5.1.3 Little Girls
  5. 5.2 Global Women's Health Drugs Sales Volume by Application
  6. 5.2.1 Global Women's Health Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Women's Health Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Women's Health Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Women's Health Drugs Sales Value by Application
  10. 5.3.1 Global Women's Health Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Women's Health Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Women's Health Drugs Sales Value Share by Application (2021-2032)
6 Women's Health Drugs Regional Sales and Value Analysis
  1. 6.1 Global Women's Health Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Women's Health Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Women's Health Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Women's Health Drugs Sales by Region (2027-2032)
  5. 6.3 Global Women's Health Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Women's Health Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Women's Health Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Women's Health Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Women's Health Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Women's Health Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Women's Health Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Women's Health Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Women's Health Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Women's Health Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Women's Health Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Women's Health Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Women's Health Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Women's Health Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Women's Health Drugs Sales Value Share by Country, 2025 VS 2032
7 Women's Health Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Women's Health Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Women's Health Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Women's Health Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Women's Health Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Women's Health Drugs Sales by Country (2027-2032)
  6. 7.4 Global Women's Health Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Women's Health Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Women's Health Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Women's Health Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Women's Health Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Women's Health Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Women's Health Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Women's Health Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Women's Health Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Women's Health Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Women's Health Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Women's Health Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Women's Health Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Women's Health Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Women's Health Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Women's Health Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Women's Health Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Women's Health Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Women's Health Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Women's Health Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Women's Health Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Women's Health Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Women's Health Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Women's Health Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Women's Health Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Women's Health Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Women's Health Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Women's Health Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Women's Health Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Women's Health Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Women's Health Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Women's Health Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Women's Health Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co.
  2. 8.1.1 Merck & Co. Company Information
  3. 8.1.2 Merck & Co. Business Overview
  4. 8.1.3 Merck & Co. Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co. Women's Health Drugs Product Portfolio
  6. 8.1.5 Merck & Co. Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Women's Health Drugs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Women's Health Drugs Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Women's Health Drugs Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 AbbVie Inc
  26. 8.5.1 AbbVie Inc Company Information
  27. 8.5.2 AbbVie Inc Business Overview
  28. 8.5.3 AbbVie Inc Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Inc Women's Health Drugs Product Portfolio
  30. 8.5.5 AbbVie Inc Recent Developments
  31. 8.6 Therapeutics MD
  32. 8.6.1 Therapeutics MD Company Information
  33. 8.6.2 Therapeutics MD Business Overview
  34. 8.6.3 Therapeutics MD Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Therapeutics MD Women's Health Drugs Product Portfolio
  36. 8.6.5 Therapeutics MD Recent Developments
  37. 8.7 Allergan Plc
  38. 8.7.1 Allergan Plc Company Information
  39. 8.7.2 Allergan Plc Business Overview
  40. 8.7.3 Allergan Plc Women's Health Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Plc Women's Health Drugs Product Portfolio
  42. 8.7.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Women's Health Drugs Value Chain Analysis
  2. 9.1.1 Women's Health Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Women's Health Drugs Sales Mode & Process
  6. 9.2 Women's Health Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Women's Health Drugs Distributors
  9. 9.2.3 Women's Health Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst